What are the Historical Developments and Current Growth Metrics of the Anaphylaxis Market?
The anaphylaxis market has seen considerable growth due to a variety of factors.
• The market scale for anaphylaxis has seen substantial growth lately. It is expected to increase from $3.24 billion in 2024 to $3.51 billion in 2025, with a compound annual growth rate (CAGR) of 8.4%.
Several factors have driven this historic growth, including the escalating occurrences of food allergies, an elevated awareness about anaphylaxis, improvement in healthcare foundation, enhanced diagnosis and treatment procedures, and a rise in the procurement of epinephrine auto-injectors.
What Is The Projected Growth Of The Anaphylaxis Market?
The anaphylaxis market is expected to maintain its strong growth trajectory in upcoming years.
• The market for anaphylaxis is predicted to experience considerable expansion in the upcoming years. Its size is anticipated to surge to $4.81 billion by 2029, with a compound annual growth rate (CAGR) of 8.2%.
Factors contributing to the growth during the forecast period include escalating urbanization and shifts in lifestyle, an increase in the number of anaphylaxis cases, growth of disposable income in emerging economies, government investments into allergy research, and advancements in emergency treatment delivery systems. Key trends projected for the forecast period encompass growing consumer need for injectable auto-injectors, incorporation of digital health solutions into anaphylaxis control, enhanced emphasis on product affordability, surge in preventative procedures and vaccinations, and heightened usage of biologics in allergy treatment.
What Are the Critical Driver Fuelling The Anaphylaxis Market's Growth?
The growth of the anaphylaxis market is expected to surge due to the increasing occurrence of food allergies. These immune system reactions, which result from intake of certain foods, induce varied symptoms that can escalate from mild to severe, including life-endangering anaphylaxis. The spike in food allergy cases can be associated with variances in dietary habits, environmental factors, and enhanced diagnosis and awareness. For individuals with allergies, anaphylaxis treatment serves as a crucial, lifesaving action, capable of reversing severe allergic reactions rapidly by alleviating symptoms like swellings, breathing difficulties, and blood pressure drops swiftly and preemptively, facilitating instant stabilization and averting fatal outcomes. Simultaneously, it equips patients to swiftly and effectively respond to future allergic episodes. The World Health Organization (WHO), a Switzerland-based United Nations (UN) organization, reported in September 2024 that around 220 million individuals across the globe are afflicted with food allergies. A sole food item might contain several allergens, and persons may exhibit allergies to multiple food types. In May 2024, the Food Standards Agency (FSA), a non-ministerial department based in the UK, revealed in its report 'Patterns and Prevalence of Adult Food Allergy' (PAFA) that over 30% of adults encountered adverse food-related reactions, and food allergies were clinically confirmed in approximately 6% of those, equating to about 2.4 million people across the UK. Thus, the increasing prevalence of food allergies is propelling the growth of the anaphylaxis market.
What Are The Principal Market Segments In The Global Anaphylaxis Industry?
The anaphylaxis market covered in this report is segmented –
1) By Drug Class: Epinephrine, Steroids, Antihistamines, Beta-antagonists, Other Drug Class
2) By Route Of Administration: Parenteral, Oral, Other Routes Of Administration
3) By Application: Food Allergy, Pollen Allergy, Dust Mites Allergy, Other Applications
Subsegments:
1) By Epinephrine: Auto-injectors, Prefilled Syringes, Vials
2) By Steroids: Corticosteroids, Glucocorticoids, Mineralocorticoids
3) By Antihistamines: H1-receptor Antagonists, H2-receptor Antagonists
4) By Beta-antagonists: Selective Beta-blockers, Non-selective Beta-blockers
5) By Other Drug Class: Leukotriene Receptor Antagonists, Mast Cell Stabilizers
Pre-Book The Anaphylaxis Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Anaphylaxis Industry?
Primary players in the anaphylaxis industry are concentrating efforts towards the evolution of enhanced epinephrine nasal spray, aimed at offering quicker, more effective medication administration in emergency situations. This nasal spray serves as a medical tool that introduces epinephrine, commonly known as adrenaline, via the nostrils for the treatment of severe allergic responses, including anaphylaxis. For example, ARS Pharmaceuticals, a biotech firm based in the US, declared in August 2024 that Neffy, their epinephrine nasal spray, had been granted approval by the Food and Drug Administration, making it the premiere and solitary needle-free remedy for type I allergies, anaphylaxis included. This avant-garde nasal spray stands as a non-invasive substitute to conventional epinephrine autoinjectors, potentially providing an accessible solution for urgent care. Neffy's objective is to enhance patient adherence by eradicating the necessity for needles, while dispensing crucial, life-preserving epinephrine swiftly during dire allergic reactions.
Who Are the Key Players In The Anaphylaxis Market?
Major companies operating in the anaphylaxis market are:
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Merck & Co. Inc.
• Bayer AG
• Novartis AG
• Sanofi SA
• AstraZeneca plc
• Abbott Laboratories
• GlaxoSmithKline Plc
• F. Hoffman-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Bausch Health Companies Inc.
• Perrigo Company plc
• Dr Reddy’s Laboratories Ltd.
• Cipla Ltd.
• Amneal Pharmaceuticals Inc.
• Mylan N.V.
• ALK-Abelló
• Stallergenes Greer
• Allergy Therapeutics
What Are The Regional Insights Into The Anaphylaxis Market?
North America was the largest region in the anaphylaxis market in 2024. The regions covered in the anaphylaxis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
